One of the more often proposed forms of medical marijuana use is considered to be the healing of glaucoma.

But the study, conducted by researchers from the Indiana Institute, demonstrated that the leading chemical component in the substance, apparently, exacerbates the primary basis of the disease: an increase in pressure from within the eyes.

The chemical substance that causes a given rise in cannabidiol pressure, or CBD, is a non-psychoactive component in cannabis, which is increasingly sold to buyers in these products like butter, chewing gum, creams and a healthy table. It is still approved in a large number of locations as a treatment for criteria such as pediatric falling disease.

The study was announced by Dec. 14 in the journal "research ophthalmology and visual Sciences".

"This study raises significant questions about the relationship between the leading components in cannabis and their impact on the eye," said Alex Stryker, an associate scientist at IU Bloomington College of Arts and Sciences' Department of mental and brain Sciences, who led the study. "This also implies the need to understand more about the possible unnecessary side effects of CBD, especially because of its use in children."

The study, which was conducted on mice, directly demonstrated, in fact, that CBD caused an increase in pressure from within the eyes by 18 % in the direction of the last at least 4 hours of subsequent application.

It was found that tetrahydrocannabinol, or THC, the leading psychoactive component of marijuana, effectively lowers pressure in the eye, as previously reported. But the study demonstrated that the introduction of CBD in combination with THC overlaps this effect.

In particular, the study demonstrated that male mice actually experienced a decrease in eye pressure of almost 30% after 8 hours of subsequent effect of only THC. More low pressure reduction of 22 % was observed later 4 hours in male mice.

The effect was weaker in female mice. After 4 hours, the pressure in this group fell by only 17%. After 8 hours, the difference in eye pressure was not measured.

The results suggest in fact that ladies have all the more chances of the least to be affected by THC, but it is not clear whether this extends to the effects of psychoactive drugs.

"This difference between men and women-and that precedent, in fact that CBD, similarly, exacerbates eye pressure, leading to the risk of glaucoma-are both considered relevant qualities of this study," said Stryker. "Yet it is worth noting, in fact the CBI as to see, actively acts opposite to the beneficial effects of THC."

Compared to the effects of these drugs on mice without specific neuroreceptors affected by THC and CBD, IU scientists have been able to identify 2 specific neuroreceptors-called CB1 and GPR18-with the support of which the 1st substance reduced pressure from within the eyes.

"There have been studies over 45 years ago that have found evidence of this, in fact that THC lowers pressure from within the eyes, but no one has ever identified certain neuroreceptors involved in this process, to this study," said Stryker. "These results have every chance to have significant results for future studies on the use of cannabis as a therapy for intraocular pressure."